Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax-based regimen for relapsed pediatric acute promyelocytic leukemia
ChiCTR2400082058Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax in Acute promyelocytic leukaemia (APL) and acute myeloid leukemia (AML), sponsored by Beijing Children's Hospital. Primary endpoints: Overall survival and Event-free survival. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
Acute promyelocytic leukaemia (APL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400082058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082058.